Search results
Should You Buy Stoke Therapeutics, Inc. (STOK) After Golden Cross?
Zacks via Yahoo Finance· 12 months agoStoke Therapeutics, Inc. (STOK) is looking like an interesting pick from a technical perspective, as...
Does Stoke Therapeutics, Inc. (STOK) Have the Potential to Rally 284.14% as Wall Street Analysts...
Zacks via Yahoo Finance· 4 months agoThe mean of analysts' price targets for Stoke Therapeutics, Inc. (STOK) points to a 284.1% upside in...
Stoke Therapeutics Inc (STOK) Reports Q3 Financial Results and Progress in Dravet Syndrome Treatment
GuruFocus.com via Yahoo Finance· 7 months agoStoke Therapeutics Inc (NASDAQ:STOK) anticipates Q1 2024 readout for Phase 1/2a study results of...
Racecourse Ground refreshed as Wrexham partner with US cold brew coffee brand
PA Media: Sport via Yahoo Sports· 1 year agoWrexham’s historic Racecourse Ground will become known as the SToK Racecourse under the terms of a...
Stoke Therapeutics, Inc. (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks via Yahoo Finance· 2 years agoAfter losing some value lately, a hammer chart pattern has been formed for Stoke Therapeutics, Inc....
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
Zacks via Yahoo Finance· 2 months agoStoke Therapeutics, Inc. STOK reported encouraging new data from two phase I/IIa studies and two...
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Boosting...
Simply Wall St. via Yahoo Finance· 1 year agoStoke Therapeutics, Inc. (NASDAQ:STOK) defied analyst predictions to release its first-quarter...
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 2 years agoStoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 4.35% and 2.07%,...
Stoke Therapeutics (NASDAQ:STOK) adds US$56m to market cap in the past 7 days, though investors from...
Simply Wall St. via Yahoo Finance· 2 years agoIt's nice to see the Stoke Therapeutics, Inc. (NASDAQ:STOK) share price up 12% in a week. But that...
Investors in Stoke Therapeutics (NASDAQ:STOK) have unfortunately lost 64% over the last three years
Simply Wall St. via Yahoo Finance· 1 year agoIf you love investing in stocks you're bound to buy some losers. But the last three years have been...